The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

Breast Cancer Res. 2010;12(3):R43. doi: 10.1186/bcr2598. Epub 2010 Jun 28.

Abstract

Introduction: Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivity of human breast cancer cells to taxanes, and the relationship between ER and MAPT.

Methods: The correlation between MAPT expression and sensitivity to taxanes was investigated in 12 human breast cancer cell lines. Alterations in cellular sensitivity to taxanes were evaluated after knockdown of MAPT expression. ER expression was knocked down or stimulated in MAPT- and ER-positive cell lines to examine the relationship between ER and MAPT. The cells were also treated with hormone drugs (tamoxifen and fulvestrant) and taxanes.

Results: mRNA expression of MAPT did not correlate with sensitivity to taxanes. However, expression of MAPT protein isoforms of less than 70 kDa was correlated with a low sensitivity to taxanes. Downregulation of MAPT increased cellular sensitivity to taxanes. MAPT protein expression was increased by stimulation with 17-beta-estradiol or tamoxifen, but decreased by ER downregulation and by fulvestrant, an ER inhibitor. The combination of fulvestrant with taxanes had a synergistic effect, whereas tamoxifen and taxanes had an antagonistic effect.

Conclusions: Expression of MAPT protein isoforms of less than 70 kDa is correlated with a low sensitivity to taxanes in breast cancer cells. ER influences MAPT expression and fulvestrant increases the sensitivity to taxanes in MAPT- and ER-positive breast cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Western
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Down-Regulation
  • Drug Synergism
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Estrogen Antagonists / pharmacology*
  • Estrogen Receptor Modulators / pharmacology
  • Female
  • Fluorescent Antibody Technique
  • Fulvestrant
  • Humans
  • Protein Isoforms
  • RNA, Messenger / genetics
  • RNA, Small Interfering / pharmacology
  • Receptors, Estrogen / antagonists & inhibitors
  • Receptors, Estrogen / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tamoxifen / pharmacology
  • Taxoids / pharmacology*
  • tau Proteins / antagonists & inhibitors
  • tau Proteins / genetics
  • tau Proteins / metabolism*

Substances

  • Estrogen Antagonists
  • Estrogen Receptor Modulators
  • MAPT protein, human
  • Protein Isoforms
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Estrogen
  • Taxoids
  • tau Proteins
  • Tamoxifen
  • Fulvestrant
  • Estradiol